OpenAI acquires startup Orchestra Bio to beef up its biotech commerce
OpenAI on Tuesday acquired a four-year-old AI biotech software program startup known as Orchestra Bio, the corporate announced on its web site. Terms of the deal weren’t disclosed, however the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI brokers that assist biotech corporations handle the trivia of drug-discovery operations, from monitoring funds to resolving scheduling points with medical trials.
OpenAI says it’s including Orchestra’s workforce and know-how to work on Rosalind, its AI mannequin for all times sciences analysis, and to its associated Rosalind Workbench software, a harness that goals to assist researchers plan experiments and analyze outcomes. OpenAI has already received some huge names as prospects for Rosalind, together with, it says, Moderna and Novo Nordisk.
The acquisition is a traditional instance of how the most important AI labs (specifically OpenAI and Anthropic) are constructing ever extra software program for the most important industries, like pharma. In the startup globe, there’s an ongoing concern that at any second, the labs will launch new options and change into rivals. In this case, Orchestra is getting absorbed, fairly than stomped out.
